<!DOCTYPE html>
<html lang="en">
<head>
<title>Central Nervous System Disease</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
<link rel="stylesheet" type="text/css" href="../../../public/css/offline.css" />
<script src="../../../public/javascripts/jquery-1.10.2.min.js"></script>
</head>
<body class="dsg-wb">

<table width="80%" class="offline">
<tr>
  <td colspan="3" class="header"><h1><a href="/">JPAC</a> <span>Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee</span></h1></td>
</tr>
<tr class="tabs">
  <td colspan="3">
              <ul>
                  <li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components"><a href="../../../dsg/wb/guidelines.html"  class="active">Whole Blood and Components</a></li>
                  <li id="ddb09bf2-3dc0-4eb2-ba57-a5db69331dd1" class="geographical-disease-risk-index"><a href="../../../dsg/gdri/guidelines.html" >Geographical Disease Risk Index</a></li>
                </ul>
        </td>
</tr>
<tr>
  <td class="spacerow" colspan="3"></td>
</tr>
<tr>
  <td class="sidebar" width="25%">
    <div class="well">
          <ul class="openContentSectionWithSubs sidebarTopHeader"><li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components sectionHead first last"><a href="../../../dsg/wb.html">Whole Blood and Components</a>
<ul class="">
<li id="42be2de8-89aa-4908-8bc8-702f9e636a81" class="a-z-search active first"><a href="../../../dsg/wb/guidelines.html">A-Z Search</a>
</li><li id="1f7e1f13-8b29-4772-ae9d-2b5cc3d59491" class="updates"><a href="../../../dsg/wb/latest-updates.html">Updates</a>
</li><li id="f83d68fb-19de-4588-9a36-a8bba0aa6494" class="drug-index"><a href="../../../dsg/wb/drug-index.html">Drug Index</a>

</li><li id="769da873-1c35-4600-8be8-d2df902570a0" class="preliminaries"><a href="../../../dsg/wb/preliminaries.html">Preliminaries</a>
<ul class="">
<li id="258895c3-f3dd-45c6-932c-3fe4795870c2" class="introduction first"><a href="../../../dsg/wb/preliminaries/introduction.html">Introduction</a>
</li><li id="ef298454-8327-4f6c-9f4a-835e437df103" class="document-and-change-control"><a href="../../../dsg/wb/preliminaries/document-and-change-control.html">Document and Change Control</a>
</li><li id="093e6463-a089-49dd-9199-c8f92559f486" class="general-principles"><a href="../../../dsg/wb/preliminaries/general-principles.html">General Principles</a>
</li><li id="96f75c3a-2c62-445b-847c-353098eaec1e" class="medication"><a href="../../../dsg/wb/preliminaries/medication.html">Medication</a>
</li><li id="ed51942d-a7fd-42f7-8269-d23b879f99ca" class="inspection-of-the-donor"><a href="../../../dsg/wb/preliminaries/inspection-of-the-donor.html">Inspection of the Donor</a>
</li><li id="99af8b5e-491b-4d67-b69a-812d81af4d7d" class="use-of-alphabetical-listing last"><a href="../../../dsg/wb/preliminaries/use-of-alphabetical-listing.html">Use of Alphabetical Listing</a>
</li></ul>
</li><li id="753eb36f-2636-414c-84ee-1004e197502d" class="appendices"><a href="../../../dsg/wb/appendicies.html">Appendices</a>
<ul class="">
<li id="e147bd96-a025-4ffa-b530-b9abefc27043" class="appendix-1---estimated-blood-volume-for-female-donors-after-nadler--by-height-and-weight first"><a href="../../../dsg/wb/appendicies/appendix-1.html">Appendix 1 - Estimated Blood Volume for Female donors (after Nadler)  by height and weight</a>
</li><li id="2f1eca54-e34f-4ece-90a4-7dfe0f210c8d" class="appendix-2---table-of-immunisations-"><a href="../../../dsg/wb/appendicies/appendix-2-table-of-immunizations.html">Appendix 2 - Table of Immunisations </a>
</li><li id="a27f8ce9-b4f6-4a9b-baf0-6f655955a9aa" class="appendix-3---maximum-permitted-ecv-for-component-donors"><a href="../../../dsg/wb/appendicies/appendix-3-maximum-permitted-extra-corporeal-volume-for-component-donors.html">Appendix 3 - Maximum permitted ECV for component donors</a>
</li><li id="90c869cb-7256-4604-8699-d8a86f78aa26" class="appendix-4---management-of-post-donation-illness last"><a href="../../../dsg/wb/appendicies/appendix-4-management-of-post-donation-illness.html">Appendix 4 - Management of post donation illness</a>
</li></ul>
</li><li id="b62a2d12-6d94-4106-92a8-1de426a4b863" class="source-files last"><a href="../../../dsg/wb/source-files.html">Source Files</a>
</li></ul>
</li></ul>
    </div>
  </td>
  <td width="5%"></td>
  <td width="70%" class="content">
    <h2>Central Nervous System Disease</h2>    

<table class="data-table"><tbody><tr class="data-row"><td class="data-label">Excludes</td><td class="data-value"><p>Cerebrovascular disease and all forms of intracranial haemorrhage.</p></td></tr><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Must not donate if has or has had:</b><br />
a) Dementia (e.g. Alzheimer's disease).<br />
<br />
b) A history of CNS disease of unknown aetiology or suspected infective origin. These include, but are not limited to,&nbsp;neurodegenerative conditions, multiple sclerosis (MS), optic neuritis, clinically isolated syndrome, and transverse myelitis.<br />
<br />
c) Malignant tumour.<br />
<br />
d) Parkinson's Disease<br />
<br />
e) If having symptoms related to hypotension while taking dopamine receptor agonist drugs such as rotigotine, ropinirole and pramipexole.</p></td></tr><tr class="data-row"><td class="data-label">Discretionary</td><td class="data-value"><p>a) Individuals who have had Bell's palsy more than four weeks ago and have discontinued any treatment for the condition for at least seven days, once investigated and discharged from specialist follow-up even if they have residual paralysis, accept.<br />
<br />
b) If the donor has been investigated and a definite diagnosis of transient global amnesia has been made, accept.<br />
<br />
c) If diagnosed with Idiopathic (benign) intracranial hypertension (IIH) and</p>


<ul>
	<li>the donor is aymptomatic, and</li>
	<li>if the donor is taking diuretics (e.g. Acetazolamide) for IIH and the dose has not changed in the last four weeks,</li>
</ul>


<p>accept.<br />
<br />
d) If taken for a condition other than Parkinson's Disease, as long as not having symptoms of hypotension related to dopamine receptor agonist drugs such as rotigotine, bromocriptine, ropinirole and pramipexole, accept.</p></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p><a href="../../../dsg/wb/guidelines/ca007-cardiovascular-disease.html">Cardiovascular Disease</a><br />
<a href="../../../dsg/wb/guidelines/cerebrovascular-disease-and-intracranial-haemorrhage.html">Cerebrovascular Disease and Intracranial Haemorrhage</a><br />
<a href="../../../dsg/wb/guidelines/ep001-epilepsy.html">Epilepsy</a><br />
<a href="../../../dsg/wb/guidelines/in005-infection-general.html">Infection - General</a><br />
<a href="../../../dsg/wb/guidelines/ne007-neurosurgery.html">Neurosurgery</a><br />
<a href="../../../dsg/wb/guidelines/pi005-pituitary-disorders.html">Pituitary Disorders</a><br />
<a href="../../../dsg/wb/guidelines/pr004-prion-associated-diseases.html">Prion Associated Diseases</a><br />
<a href="../../../dsg/wb/guidelines/st003-steroid-therapy.html">Steroid Therapy</a><br />
<a href="../../../dsg/wb/guidelines/se007-self-catheterization.html">Urinary Catheterisation</a></p></td></tr><tr class="data-row"><td class="data-label">Additional Information</td><td class="data-value"><p><b>Donor safety:</b><br />
<br />
Transient global amnesia is a temporary and isolated disorder of memory. Affected individuals are usually over 50 years of age and there is an association with migraine. There is no association with cerebrovascular disease.<br />
<br />
Idiopathic or benign intracranial hypertension is a raised intracranial pressure where no mass or other disease is present.<br />
<br />
Parkinson's disease is a movement disorder that can make venepuncture difficult and lead to damage to the donor's arm.&nbsp;It is also treated with dopamine receptor agonist drugs (e.g. rotigotine, bromocriptine, ropinirole and pramipexole) that can cause hypotension and fainting.<br />
<br />
<b>Recipient safety:</b><br />
<br />
It is thought that degenerative brain disease in the form of vCJD has been transmitted by blood transfusion. Often the exact cause of a degenerative brain condition only becomes known after death. For this reason, when there is any doubt as to the underlying cause of a brain condition, it is considered safest not to accept a donation.</p></td></tr><tr class="data-row"><td class="data-label">Information</td><td class="data-value"><p>This is a requirement of the Blood Safety and Quality Regulations 2005.</p></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>A discretion to accept donors on treatment for IIH has been added.</p></td></tr><tr class="data-row"><td class="data-label">Donor Information</td><td class="data-value"><p>If you wish to obtain more information regarding a personal medical issue, please contact your <a href="../../../dsg/wb/guidelines/nn099-national-help-lines.html">National Help Line</a>.<br />
<br />
Please do not contact this web site for personal medical queries, as we are not in a position to provide individual answers.</p></td></tr></tbody></table>
<div class="pull-right attachments"><div class="cms images">
  
</div></div>

  
<dl class="update-information"><dt class="data-label"><h4>Update Information</h4></dt><dd class="data-value"><p>This entry was last updated in:<br />
WB-DSG Edition 203&nbsp;Release 73</p></dd></dl>  </td>
</tr>
</table>
</body>
</html>